Gynion is a Women’s Health startup with a mission to offer millions of women worldwide safe, effective, and affordable in-office therapies for common gynecological conditions that improve and save lives.

Gynion is developing a therapeutic platform that presents an opportunity to commercialize several products, including Clarablex and Menorrx, addressing unmet needs in several markets with a combined value of $14 Billion.

Clarablex^TM is a topical gel for multiple indications in gynecology, including the treatment of cervical intraepithelial neoplasia (CIN) to prevent cervical cancer and other diseases caused by human papillomavirus (HPV). It is a simple and non-invasive treatment ready for immediate use by any healthcare provider trained in cervical cancer screening as soon as the woman is diagnosed with CIN. Clarablex’s affordability will enable all screening centers, even those in low- and middle-income countries, to stock it, removing any obstacles to healthcare access and allowing more women to receive timely treatment to prevent cervical cancer.

Menorrx^TM is a therapy for Heavy Menstrual Bleeding (HMB). It is simpler, easier to use, and will cost significantly less than the alternatives. Because of the high cost and clinical limitations of the available options, millions of women receive no treatment or are compelled to undergo a hysterectomy. Menorrx presents a substantial opportunity to change that both in developed markets and low-resource countries.